仁新醫藥股份有限公司

Climate Impact & Sustainability Data (2022)

Reduced waste generation by using reusable materials in pre-clinical experiments and outsourcing the handling of toxic chemicals to professional companies.

Collaborated with domestic well-known institutions on projects to study the genetic mutations of Taiwanese populations with AMD and Stargardt disease, creating a database of patients with these diseases to improve the quality of medical care in Taiwan.

Established a board performance evaluation mechanism, implemented a board performance evaluation in December 2022, and used the results to refer to director compensation and nomination for reappointment.
Established an accounting professional judgment procedure, accounting policy and estimation change process management operation, seal use management operation, related party transaction management operation, and application for suspension and restoration of OTC stock counter trading operation procedure.

Long-term Goals:

Medium-term Goals:

Complete phase 3 clinical trials for Stargardt disease and late-stage geographic atrophy (GA) AMD.
Complete licensing or collaboration negotiations for acute leukemia.

Short-term Goals:

Complete phase 1b/2 clinical trials for Stargardt disease in adolescents, and commence patient recruitment for phase 3 clinical trials for Stargardt disease and late-stage geographic atrophy (GA) AMD.
Commence patient recruitment for phase 1/2 clinical trials for acute leukemia.

High risk and capital requirements in new drug development.
Supply chain disruptions due to climate events could affect the progress of drug development.
Data limitations or exclusions in ESG reporting.

Developed alternative sourcing strategies for suppliers.
Implemented a diversified product portfolio to mitigate risks.
Established multiple funding channels to ensure stable funding for drug development projects.
Established a complete internal control mechanism, including monthly audits by the audit department and annual internal control system self-assessments across all group companies.

Frameworks Used: IFRS